[1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases

Patent metadata

Field	Value
Publication number	US-9944650-B2
Application number	US-201515329274-A
Country	US
Kind code	B2
Filing date	Jul 24, 2015
Priority date	Jul 28, 2014
Publication date	Apr 17, 2018
Grant date	Apr 17, 2018

Abstract

The invention concerns compounds of Formula (I) (Formula (I)) or pharmaceutically-acceptable salts thereof, wherein R 1 , R 2 and n have any of the meanings defined herein before in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.

First claim

The invention claimed is:

1. A compound or a pharmaceutically acceptable salt thereof, which compound is:
(R)-4-(2-(4-(1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)-1,3-dimethylpiperazin-2-one.

2. A compound or a pharmaceutically acceptable salt thereof, of Formula (IA):

3. A compound as claimed in claim 2 of Formula (IA).

4. A compound of Formula (IA) as claimed in claim 3 in a crystalline form with an XRPD pattern with specific peaks at about 2-theta=20.9, 16.7, 20.2, 21.2, 27.4, 18.0, 16.8, 23.6, 15.1 and 15.5° plus or minus 0.2° 2-theta, measured using CuKα radiation.

5. A co-crystal of the compound of Formula (IA), according to claim 3 , and the co-former molecule 6-hydroxy-2-naphthoic acid.

6. A co-crystal of the compound of Formula (IA), according to claim 3 , and 6-hydroxy-2-naphthoic acid obtainable by the steps of
i) mixing a solution of the compound of Formula (IA) in suitable solvent with 6-hydroxy-2-naphthoic acid co-crystal in a suitable solvent; and
ii) drying the resultant mixture from step (i) to obtain a solid.

7. A pharmaceutical composition comprising a compound of Formula (IA) or a pharmaceutically acceptable salt thereof, as claimed in claim 2 , and a pharmaceutically acceptable diluent or carrier.

8. A pharmaceutical composition comprising a co-crystal of the compound of Formula (IA) as claimed in claim 5 , and a pharmaceutically acceptable diluent or carrier.

Assignees

• Astrazeneca Ab

Inventors

• Bradbury Robert Hugh
• Rabow Alfred Arthur
• Waring Michael James
• Mccabe James Francis
• Glossop Steven Christopher
• Mahmood Arshed
• Cotter Zoe Ann

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• E21B7/06

  Deflecting the direction of boreholes · CPC title

• C07D487/04 Primary

  Ortho-condensed systems · CPC title

• C07B2200/13

  Crystalline forms, e.g. polymorphs · CPC title